SEARCH

SEARCH BY CITATION

References

  • Abramovitz M., Adam M., Boie Y. et al. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483, 285293.
  • Aid S. and Bosetti F. (2007) Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging. Brain Res. Bull. 73, 108113.
  • Barnett M. H. and Prineas J. W. (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55, 458468.
  • Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C. and Andreasson K. (2004) PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 56, 240248.
  • Bos C. L., Richel D. J., Ritsema T., Peppelenbosch M. P. and Versteeg H. H. (2004) Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol. 36, 11871205.
  • Bramow S., Frischer J. M., Lassmann H., Koch-Henriksen N., Lucchinetti C. F., Sorensen P. S. and Laursen H. (2010) Demyelination versus remyelination in progressive multiple sclerosis. Brain 133, 29832998.
  • Carlson N. G., Hill K. E., Tsunoda I., Fujinami R. S. and Rose J. W. (2006) The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J. Neuroimmunol. 174, 2131.
  • Carlson N. G., Rojas M. A., Black J. D., Redd J. W., Hille J., Hill K. E. and Rose J. W. (2009) Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J. Neuroinflammation 6, 5.
  • Carlson N. G., Rojas M. A., Redd J. W., Tang P., Wood B., Hill K. E. and Rose J. W. (2010) Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death. J. Neuroinflammation 7, 25.
  • Cimino P. J., Keene C. D., Breyer R. M., Montine K. S. and Montine T. J. (2008) Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr. Med. Chem. 15, 18631869.
  • Davies N. M., McLachlan A. J., Day R. O. and Williams K. M. (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokine 38, 225242.
  • Dore-Duffy P., Donaldson J. O., Koff T., Longo M. and Perry W. (1986) Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 36, 15871590.
  • Dore-Duffy P., Ho S. Y. and Donovan C. (1991) Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology 41, 322324.
  • Farooqui A. A., Horrocks L. A. and Farooqui T. (2007) Modulation of inflammation in brain: a matter of fat. J. Neurochem. 101, 577599.
  • Franco-Pons N., Torrente M., Colomina M. T. and Vilella E. (2007) Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol. Lett. 169, 205213.
  • Greco A., Minghetti L., Sette G., Fieschi C. and Levi G. (1999) Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53, 18761879.
  • Groebe A., Clarner T., Baumgartner W., Dang J., Beyer C. and Kipp M. (2009) Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 8, 163174.
  • Hall A., Giese N. A. and Richardson W. D. (1996) Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors. Development 122, 40854094.
  • Hesse A., Wagner M., Held J., Bruck W., Salinas-Riester G., Hao Z., Waisman A. and Kuhlmann T. (2010) In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. Neurobiol. Dis. 37, 362369.
  • Hinz B., Renner B. and Brune K. (2007) Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. Nat. Clin. Pract. Rheumatol. 3, 552560; quizz 551 p following 589.
  • Kihara Y., Matsushita T., Kita Y., Uematsu S., Akira S., Kira J., Ishii S. and Shimizu T. (2009) Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc. Natl Acad. Sci. USA 106, 2180721812.
  • Kipp M., Clarner T., Dang J., Copray S. and Beyer C. (2009) The cuprizone animal model: new insights into an old story. Acta Neuropathol. 118, 723736.
  • Kiriyama M., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y. and Narumiya S. (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122, 217224.
  • Kutzelnigg A., Lucchinetti C. F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J. E. and Lassmann H. (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 27052712.
  • Liu L., Belkadi A., Darnall L. et al. (2010) CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 13, 319326.
  • Matsushima G. K. and Morell P. (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 11, 107116.
  • Muthian G., Raikwar H. P., Johnson C., Rajasingh J., Kalgutkar A., Marnett L. J. and Bright J. J. (2006) COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J. Clin. Immunol. 26, 7385.
  • Neu I. S., Metzger G., Zschocke J., Zelezny R. and Mayatepek E. (2002) Leukotrienes in patients with clinically active multiple sclerosis. Acta Neurol. Scand. 105, 6366.
  • Ni J., Shu Y. Y., Zhu Y. N. et al. (2007) COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J. Neuroimmunol. 186, 94103.
  • Norkute A., Hieble A., Braun A., Johann S., Clarner T., Baumgartner W., Beyer C. and Kipp M. (2009) Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J. Neurosci. Res. 87, 13431355.
  • Pang Y., Campbell L., Zheng B., Fan L., Cai Z. and Rhodes P. (2010) Lipopolysaccharide-activated microglia induce death of oligodendrocyte progenitor cells and impede their development. Neuroscience 166, 464475.
  • Palumbo S., Toscano C. D., Parente L., Weigert R. and Bosetti F. (2011) Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination. Prostaglandins Leukot Essent Fatty Acids 85, 4352.
  • Reder A. T., Thapar M., Sapugay A. M. and Jensen M. A. (1995) Eicosenoids modify experimental allergic encephalomyelitis. Am. J. Ther. 2, 711720.
  • Rose J. W., Hill K. E., Watt H. E. and Carlson N. G. (2004) Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J. Neuroimmunol. 149, 4049.
  • Schmued L. and Slikker W. Jr (1999) Black-gold: a simple, high-resolution histochemical label for normal and pathological myelin in brain tissue sections. Brain Res. 837, 289297.
  • Shi J., Johansson J., Woodling N. S., Wang Q., Montine T. J. and Andreasson K. (2010) The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J. Immunol. 184, 72077218.
  • Torkildsen O., Brunborg L. A., Myhr K. M. and Bo L. (2008) The cuprizone model for demyelination. Acta Neurol. Scand. Suppl. 188, 7276.
  • Toscano C. D., Prabhu V. V., Langenbach R., Becker K. G. and Bosetti F. (2007) Differential gene expression patterns in cyclooxygenase-1 and cyclooxygenase-2 deficient mouse brain. Genome Biol. 8, R14.
  • Toscano C. D., Ueda Y., Tomita Y. A., Vicini S. and Bosetti F. (2008) Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice. Brain Res. Bull. 75, 598609.
  • Tumani H., Hartung H. P., Hemmer B., Teunissen C., Deisenhammer F., Giovannoni G. and Zettl U. K. (2009) Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 35, 117127.
  • Wilson H. C., Scolding N. J. and Raine C. S. (2006) Co-expression of PDGF alpha receptor and NG2 by oligodendrocyte precursors in human CNS and multiple sclerosis lesions. J. Neuroimmunol. 176, 162173.
  • Wingerchuk D. M., Benarroch E. E., O’Brien P. C., Keegan B. M., Lucchinetti C. F., Noseworthy J. H., Weinshenker B. G. and Rodriguez M. (2005) A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 64, 12671269.
  • Yao C., Sakata D., Esaki Y., Li Y., Matsuoka T., Kuroiwa K., Sugimoto Y. and Narumiya S. (2009) Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15, 633640.